Find side effects reporting information at the bottom of this page
If you are a UK Healthcare Professional, please visit our Healthcare Professional website here

Metalyse 25mg (tenecteplase) for the treatment of Acute Ischaemic Stroke

Metalyse® 25mg (tenecteplase) - Product

Metalyse® 25mg (tenecteplase)

This page is intended to provide reference information for UK members of the public, patients prescribed Metalyse 25mg (tenecteplase) and their carers. This information is not intended to replace the advice of a healthcare professional.

 

Patient Information Leaflet

The Patient Information Leaflet is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using this medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

If you are in Great Britain, click the link below to access this information

If you are in Northern Ireland, click the link below to access this information

 

Summary of Product Characteristics

The Summary of Product Characteristics (SmPC) tells healthcare professionals, such as doctors, pharmacists and nurses, how to prescribe and use this medicine correctly. The information in the Patient Information Leaflet and Summary of Product Characteristics are not intended to replace the advice of a healthcare professional.

If you are in Great Britain, click the link below to access this information

If you are in Northern Ireland, click the link below to access this information

Public Assessment Report

The Public Assessment Report (PAR) provides public information on a medicine, including how it was assessed by the MHRA (GB) and the EMA (NI).

If you are in Great Britain, click the link below to access this information

If you are in Northern Ireland, click the link below to access this information

NP-GB-104968 V1October 2024